Association of clinical trial enrollment and survival using contemporary therapy for pediatric acute lymphoblastic leukemia.
Diana J MokeMatthew J OberleyDeepa BhojwaniChintan ParekhEtan OrgelPublished in: Pediatric blood & cancer (2017)
While early studies reported superior survival for cancer patients enrolled on clinical trials, recent findings are inconclusive. We investigated the association between enrollment on contemporary trials and event-free survival (EFS) in pediatric B-cell acute lymphoblastic leukemia (B-ALL). In a retrospective cohort of 274 children (1-21 years) treated for B-ALL from 2008 to 2015, 55.5% enrolled with no disparity in enrollment by age, sex, or ethnicity. Three-year EFS was similar for enrolled and not enrolled patients (90.1% [95% CI, 82.5-94.5] versus 86.5% [95% CI, 77.7-92.0]). Clinical trial enrollment did not affect pediatric B-ALL survival, albeit in a limited-size cohort treated at a single academic institution.
Keyphrases
- clinical trial
- free survival
- acute lymphoblastic leukemia
- health insurance
- newly diagnosed
- end stage renal disease
- phase ii
- allogeneic hematopoietic stem cell transplantation
- ejection fraction
- double blind
- affordable care act
- open label
- phase iii
- study protocol
- peritoneal dialysis
- chronic kidney disease
- young adults
- acute myeloid leukemia
- medical students